Create a management protocol for sepsis in the ICU
Reading Document
Medical Text Search
sepsis septic shock ICU management protocol diagnosis criteria
Medical Text Search
sepsis fluid resuscitation vasopressors antimicrobial therapy source control
GradeResponse
GradeResponse
Medical Text Search
sepsis corticosteroids organ dysfunction ventilation renal replacement therapy
Here is a comprehensive ICU Sepsis Management Protocol based on Sepsis-3 definitions and current guidelines (Harrison's Principles of Internal Medicine, 21st Ed.; Surviving Sepsis Campaign):
ICU Sepsis Management Protocol
1. Definitions (Sepsis-3)
| Condition | Criteria |
|---|---|
| Sepsis | Suspected infection + acute organ dysfunction (SOFA score increase ≥2 from baseline) |
| Septic Shock | Sepsis + vasopressor requirement to maintain MAP ≥65 mmHg + serum lactate >2.0 mmol/L despite adequate fluid resuscitation |
| SOFA domains | Respiratory (PaO₂/FiO₂), Coagulation (platelets), Liver (bilirubin), Cardiovascular (MAP/vasopressors), CNS (GCS), Renal (creatinine/urine output) |
qSOFA (screening tool outside ICU): ≥2 of: RR ≥22/min, altered mentation, SBP ≤100 mmHg
2. Hour-1 Bundle (Immediate Actions)
Initiate as soon as sepsis or septic shock is recognized:
- Measure lactate — if initial lactate >2 mmol/L, remeasure within 2 hours
- Blood cultures ×2 — before antibiotics (minimum 10 mL per bottle); also culture other relevant sites (urine, sputum, wound)
- Broad-spectrum antibiotics — administer within 1 hour of recognition
- IV fluid resuscitation — 30 mL/kg crystalloid within 3 hours
- Vasopressors — if hypotension persists after initial fluids, start to target MAP ≥65 mmHg
3. Fluid Resuscitation
| Parameter | Recommendation |
|---|---|
| Initial bolus | 30 mL/kg IV crystalloid within 3 hours |
| Preferred fluid | Balanced crystalloids (Lactated Ringer's) or normal saline |
| Avoid | Hydroxyethyl starches (HES), gelatins |
| Reassessment | Hemodynamic reassessment after each bolus (HR, BP, UO, cap refill) |
| Dynamic predictors of fluid responsiveness | Pulse pressure variation (PPV), stroke volume variation (SVV), passive leg raise (PLR) test |
| Lactate clearance target | ≥10% reduction every 2 hours; normalize toward <2 mmol/L |
| Albumin | Consider 4% albumin when large volumes of crystalloid have been given |
Caution: Avoid aggressive fluid resuscitation beyond the initial phase — fluid overload worsens outcomes. Use dynamic assessment to guide further boluses.
4. Vasopressors & Inotropes
| Agent | Role | Dose |
|---|---|---|
| Norepinephrine | First-line vasopressor | 0.01–3 mcg/kg/min; titrate to MAP ≥65 mmHg |
| Vasopressin | Add-on to reduce norepinephrine dose | 0.03–0.04 units/min (fixed dose) |
| Epinephrine | Second-line if NE insufficient | 0.01–0.5 mcg/kg/min |
| Dopamine | Avoid except in bradycardia/low tachyarrhythmia risk | 5–20 mcg/kg/min |
| Dobutamine | Myocardial dysfunction with low CO | 2–20 mcg/kg/min |
| Angiotensin II | Refractory vasodilatory shock | 20–200 ng/kg/min |
Central venous access is strongly preferred for vasopressor administration. Peripheral delivery is acceptable short-term in emergency situations.
5. Antimicrobial Therapy
5.1 Timing
- Administer within 1 hour of sepsis/septic shock recognition
- Every hour of delay in antibiotic administration is associated with increased mortality
5.2 Empiric Regimens by Source
| Suspected Source | Empiric Regimen |
|---|---|
| Unknown / septic shock | Pip-tazo 4.5 g IV q6h or Meropenem 1 g IV q8h + Vancomycin 25–30 mg/kg loading dose |
| Pneumonia (CAP) | Ceftriaxone + Azithromycin |
| Pneumonia (HAP/VAP) | Pip-tazo or Cefepime ± Vancomycin/Linezolid ± Antipseudomonal coverage |
| Abdominal | Pip-tazo or Meropenem ± Metronidazole |
| UTI/Urosepsis | Ceftriaxone or Pip-tazo |
| Skin/Soft tissue (SSTI) | Vancomycin + Pip-tazo |
| Meningitis | Ceftriaxone + Vancomycin + Ampicillin (if Listeria risk) + Dexamethasone |
| Neutropenic fever | Cefepime or Meropenem ± Vancomycin ± Antifungal |
5.3 De-escalation
- Review cultures at 48–72 hours and de-escalate to narrowest effective agent
- Target antibiotic duration: 5–7 days for most sources; guided by procalcitonin when available
- Reassess daily for discontinuation if infection resolved or alternative diagnosis confirmed
6. Source Control
- Identify and control the infectious source within 6–12 hours of diagnosis
- Actions: drainage of abscess, debridement of infected tissue, removal of infected devices/catheters, surgical intervention when indicated
- Remove intravascular access devices if suspected as the source after placing new access
7. Corticosteroids
| Indication | Agent & Dose |
|---|---|
| Refractory septic shock (MAP not maintained despite adequate fluids + vasopressors) | Hydrocortisone 200 mg/day IV (50 mg q6h or 200 mg continuous infusion) |
| Consider in patients requiring high-dose vasopressors | Taper when vasopressors no longer required |
| Do not use if shock has resolved | — |
8. Organ Support
8.1 Respiratory
| Parameter | Target |
|---|---|
| Indication for intubation | Refractory hypoxemia, increased WOB, encephalopathy, inability to protect airway |
| Tidal volume | 6 mL/kg ideal body weight (lung-protective ventilation) |
| Plateau pressure | ≤30 cmH₂O |
| PEEP | Higher PEEP strategy for moderate-severe ARDS |
| SpO₂ target | 92–96% |
| Prone positioning | ≥12–16 hours/day if PaO₂/FiO₂ <150 on FiO₂ ≥0.6 |
| Neuromuscular blockade | Consider for 48 hours if P/F <150 and dyssynchrony |
| Conservative fluid strategy | Once resuscitation complete — avoid fluid overload |
8.2 Renal
| Parameter | Recommendation |
|---|---|
| Avoid nephrotoxins | Hold NSAIDs, aminoglycosides, contrast when possible |
| CRRT / IHD | Indicated for: refractory metabolic acidosis, hyperkalemia, fluid overload, uremia |
| Preferred modality | CRRT preferred in hemodynamically unstable patients |
| Avoid early RRT | No benefit to prophylactic RRT in early AKI without above indications |
8.3 Hematologic / Coagulation
| Parameter | Recommendation |
|---|---|
| Hemoglobin target | Transfuse if Hgb <7 g/dL (threshold <8 g/dL post-MI or severe ischemia) |
| Platelet transfusion | <10,000/µL prophylactically; <20,000 if bleeding risk; <50,000 before procedures |
| FFP / Cryo | Only for active bleeding or invasive procedures with coagulopathy |
| DVT prophylaxis | Low-molecular-weight heparin (preferred) or UFH; mechanical compression if anticoagulation contraindicated |
8.4 Glucose Management
- Target blood glucose: 140–180 mg/dL (7.8–10 mmol/L)
- Use IV insulin infusion protocol in ICU
- Avoid hypoglycemia (<70 mg/dL) — check glucose every 1–2 hours when on insulin drip
8.5 Nutrition
- Initiate enteral nutrition within 24–48 hours when hemodynamically stable
- Avoid parenteral nutrition in the first 7 days unless enteral route is unavailable
- Caloric target: 25–30 kcal/kg/day after 48 hours
9. Monitoring & Reassessment
| Parameter | Frequency |
|---|---|
| Lactate | At 0, 2h, 6h — until normalized |
| Blood cultures | Before antibiotics; repeat if persistent bacteremia |
| CBC, BMP, LFTs, coagulation | Every 6–12 hours in acute phase |
| Hemodynamic monitoring | Continuous: HR, MAP, SpO₂, UO (target ≥0.5 mL/kg/h) |
| Procalcitonin | At baseline, then every 48h — guides de-escalation |
| Echocardiography | If hemodynamic instability, suspected cardiac dysfunction |
10. SOFA Score Reference
| Organ System | 0 | 1 | 2 | 3 | 4 |
|---|---|---|---|---|---|
| Respiratory (P/F ratio) | ≥400 | 300–399 | 200–299 | 100–199 | <100 |
| Coagulation (Platelets ×10³/µL) | ≥150 | 100–149 | 50–99 | 20–49 | <20 |
| Liver (Bilirubin mg/dL) | <1.2 | 1.2–1.9 | 2.0–5.9 | 6.0–11.9 | ≥12.0 |
| Cardiovascular (MAP/vasopressors) | MAP ≥70 | MAP <70 | Dopamine ≤5 or dobutamine | Dopa 5–15 or Epi/NE ≤0.1 | Dopa >15 or Epi/NE >0.1 |
| CNS (GCS) | 15 | 13–14 | 10–12 | 6–9 | <6 |
| Renal (Creatinine mg/dL or UO) | <1.2 | 1.2–1.9 | 2.0–3.4 | 3.5–4.9 or UO <500 mL/d | ≥5.0 or UO <200 mL/d |
11. Special Considerations
| Situation | Modification |
|---|---|
| Immunocompromised / neutropenia | Broader antifungal coverage (consider echinocandin); avoid unnecessary steroids |
| MRSA risk (prior colonization, HCAP, skin source) | Add vancomycin or linezolid empirically |
| Fungal sepsis risk (prolonged ICU, TPN, immunosuppression, recent surgery) | Add echinocandin (micafungin, caspofungin) empirically |
| Meningitis suspected | Do NOT delay antibiotics for LP if CT needed |
| Pregnancy | Avoid tetracyclines, fluoroquinolones; prefer beta-lactams; early obstetric consultation |
| End-stage renal disease | Adjust antimicrobial dosing; avoid nephrotoxins; CRRT if needed |
Summary Algorithm
SUSPECTED INFECTION
↓
SOFA ≥2? → YES → SEPSIS
↓
Vasopressors + Lactate >2 mmol/L? → YES → SEPTIC SHOCK
↓
HOUR-1 BUNDLE:
✔ Lactate
✔ Blood cultures ×2
✔ Broad-spectrum antibiotics (within 1h)
✔ 30 mL/kg IV crystalloid (if hypotension or lactate ≥4)
✔ Vasopressors if MAP <65 mmHg
↓
REASSESS at 2–6h:
✔ Lactate clearing?
✔ Hemodynamics stable?
✔ Source identified/controlled?
↓
ONGOING ICU CARE:
Lung-protective ventilation | CRRT if needed
Glycemic control | Hydrocortisone if refractory shock
De-escalate antibiotics at 48–72h
DVT/GI/pressure ulcer prophylaxis
Early enteral nutrition
Based on: Harrison's Principles of Internal Medicine, 21st Ed. (pp. 8257, 8273); Surviving Sepsis Campaign International Guidelines; Sepsis-3 Consensus Definitions (JAMA 2016).
This is a shared conversation. Sign in to Orris to start your own chat.